The Big 3 automakers spent 35 percent more in the Indianapolis area to provide health care for workers and non-elderly retirees than they did in other auto-heavy cities—and two-thirds of that difference can be blamed on “excess prices” by Indianapolis hospitals.
Eli Lilly and Co. plans to invest about $440 million in a new pharmaceutical plant at an existing company site in County Cork in southern Ireland. The facility in Kinsale will require as many as 200 skilled employees when fully operational.
3-D scans match former hospital with building plans.
Excluding investment gains and one-time charges, CNO’s operations generated $60.1 million, or 22 cents per share, in the fourth quarter, up 16 percent from the same period last year.
The once fast-growing, Indianapolis-based disease-management company listed in court papers on Tuesday liabilities of nearly $5.7 million and assets of just $125,864.
The U.S. economy is showing signs of bouncing back and, if it does, look for drugmakers and medical-device companies to benefit. But if the economy has another summer stall like last year, expect health insurers to benefit.
After years of screaming by employers that spiraling health care spending is crimping their profits and forcing them to hold down wages, the economic impact study released last week by Indiana University Health suggests health care spending is an unmitigated blessing to the Indiana economy.
The city of Indianapolis approved the project after accepting Mainstreet Property Group’s offer to purchase the property at 16th Street and Arlington Avenue for $912,500.
Indiana is battling its second measles outbreak in two years, even though its vaccination rate exceeds the national average. Health officials say the cases, traced to a Super Bowl event, illustrate just how vulnerable the public is to exposure from sources at home and abroad.
Disease management company’s demise in August pushed its CEO Stephanie DeKemper into personal bankruptcy in late December and the company itself will file its own bankruptcy case as early as this week.
WellPoint Inc. finally canned the head of its consumer business after a string of disappointing results, and the move hasn’t further spooked the company’s jittery investors. Although that’s not saying much.
In the 10 years BioCrossroads has been promoting life sciences in Indiana, the effort has netted more than 330 new companies, an infusion of more than $330 million in venture capital, a tripling of exports, and a growing number of mentions in national reports on life sciences.
Analysts say the company has struggled to generate the consistent earnings that rivals have, in part because of mispricing of its Medicare Advantage senior coverage.
A Carmel-based health insurer once owned by Conseco Inc. is being sued for refusing to pay claims for in-home care submitted by California senior citizens.
Roche Diagnostics Corp.’s North American business, which is headquartered in Indianapolis, posted a 4-percent boost in sales last year on the strength of its fluid analyzer business unit, even though its diabetes sales fell.
Indiana companies landed just $14.1 million in venture funding last year, the lowest amount of capital flowing to the state’s health care sector since BioEnterprises began tracking such deals in 2005.
For drugmakers, the golden era of the 1990s and early part of the last decade, when they seemed to effortlessly churn out new multibillion-dollar pills for the masses along with double-digit quarterly profit increases, is not even in the rearview mirror any more.
Indianapolis-based Baldwin & Lyons Inc. turned a profit in the fourth quarter, but it wasn’t enough to erase a dismal 2011 plagued by catastrophic losses.
The Indianapolis-based unit of Dow Chemical Co. saw earnings grow to $142 million, a fourth-quarter record and double the $72 million reported for the 2010 period.
Eli Lilly and Co. is among about a half-dozen companies interested in buying a stake in Mustafa Nevzat Ilac Sanayii AS in a deal that may value the Turkish drugmaker at $1 billion, sources say.
